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ABSTRACT 
Rationale:  Idiopathic Pulmonary Fibrosis (IPF) is a progressively fatal interstitial lung 
disease (ILD) with no known cure. Pathogenic variants in the telomere maintenance and surfactant 
pathways have been implicated in both familial and sporadic IPF, although a significant fraction 
of familial IPF cases remain uncharacterized. 
Methods:  A panel of patients with clinical diagnoses of IPF were selected for whole 
genome sequencing (WGS) at the Simmons Center for Interstitial Lung Disease of UPMC. 
Selected patients had comorbid hematologic malignancies or family histories suggestive of 
familial disease. 25X WGS was performed and all candidate variants were verified by bi-
directional sanger sequencing. Protein alignment was done for all candidate variants to determine 
the phylogenetic conservation. A three-generation pedigree was constructed for participants and 
included ages and health status of all family members, if known. Targeted questions related to 
associated malignancies of IPF and telomere mediated disease were additionally ascertained.  
Results:  Six patients underwent WGS, two patients have pending results. Patients included 
three women and three men ranging in age from 60 to 83 years old. Five patients had a family 
history consistent with familial pulmonary fibrosis and one patient had a comorbid hematologic 
malignancy (a myelodysplastic syndrome). Of the four patients sequenced, two patients were 
found to have exonic variants in the telomere maintenance genes RTEL1 and TERT. Two of the 
four patients who were familial by report had no known exonic variants suggesting the possibility 
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of noncoding variants, potentially novel genes, or shared environmental exposures. The two 
patients, with results pending, have family histories that are consistent with familial disease and 
are concerning for telomere-related co-morbidities. 
Conclusions:  Future studies will require confirmation of these new variants through 
functional studies or testing segregation in affected families. As genetic variants associated with 
IPF continue to be identified and characterized, genetic counseling is likely to have an increasing 
place in the management of IPF patients and their families. Furthermore, studies like these will 
contribute to the growing body of literature and further impact the field of public health by 
improving clinical guidelines on the use of genetics in IPF management.  
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1.0  INTRODUCTION 
Idiopathic pulmonary fibrosis (IPF) is a type of idiopathic interstitial pneumonia (IIP) 
which results in irreversible scarring of the lungs.1 This progressive lung disease often results in 
death 3-5 years following a diagnosis, which is typically in the sixth or seventh decade of life.2,3 
In many cases, the cause of IPF is unknown, however there are several known risk factors. 
Smoking, environmental, and occupation exposures are thought to contribute, although the risks 
are not empirically quantified. In addition to modifiable lifestyle factors, one of the most 
underappreciated risk factors in IPF is family history. Up to 20% of individuals have familial 
pulmonary fibrosis, meaning they report having at least one other family member with the disease.4 
The disease course of IPF is complicated in many patients due to the presence of multiple 
co-morbidities. 5-8 Co-morbidities not only affect treatment options, but confound studies aimed at 
deciphering the effectiveness of interventions.9,10 Overall, treatment options are limited, some 
interventions try to treat the symptoms, others aim to prevent further lung fibrosis. Two FDA-
approved medications attempt to limit fibrosis to the lung; however, these do not alleviate any 
symptoms for patients.11,12 Further, some patients choose to be evaluated for, and undergo, a lung 
transplant. Lung transplants may prolong survival, but many patients suffer post-transplant 
complications.13-15 In addition, many patients are excluded from lung transplants due to age, co-
morbidities, and other factors. One of those factors is a pathogenic variant in a gene associated 
with IPF.  
Pathogenic variants in genes have been established in up to 20% of families. Pathogenic 
variants have also been found in approximately 11% of patients with reportedly sporadic IPF.16 
The genes that have been implicated in IPF are found in the surfactant and telomere biology 
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pathway. In the telomere pathway, patients have shorter telomeres, this drives the progression of 
the disease.17 This may be due to pathogenic variants in genes in the telomere pathway. As 
telomeres shorten in subsequent generations, different, and more severe manifestations of the 
disease appear, which is termed genetic anticipation.18,19 For those patients who choose to undergo 
a lung transplant, if they have shorter telomeres (<10th percentile) or a pathogenic variant in an 
implicated gene, they may be a risk for post-transplant complications.13-15 
The overall goal of this study is to characterize and better understand the genetics of IPF. 
This study aims to identify candidate genes in IPF and examine the segregation in families in hopes 
to add to the growing knowledge regarding the genetics of IPF. By constructing and analyzing 
pedigrees of affected probands, it will aid in confirming segregation within families, and to 
establish other related malignancies or associated phenotypic features in the family. 
The specific aims of this study are as follows: 
• Identify and characterize possible pathogenic variants that can be implicated in IPF 
in probands affected with IPF to identify candidate genes 
• Ascertain the family history of the proband in order to construct a pedigree. The 
pedigrees can then be analyzed for possible inheritance patterns and genetic 
anticipation of the disease in family members. This will help establish affected and 
unaffected relatives on the pedigree for whom samples could be obtained to test the 
segregation of possible pathogenic variants. 
This study will be the first of its kind at the Simmons Center for Interstitial Lung Disease 
at UPMC and will help expand the understanding of the role of genetics in IPF. Additionally, the 
information generated from this research study has the potential to aid in the development of 
guidelines for genetic counseling in IPF patients. In turn, future IPF patients and their family 
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members could benefit from such knowledge and expertise. As more genetic information becomes 
known about IPF and genetic testing of asymptomatic individuals becomes clinically available, it 
will become important to ensure that individuals who decide to undergo testing are properly 
informed of the risks, benefits, and limitations of genetic testing. This is especially imperative in 
the case of IPF as it has no known long-lasting cure and the possibility of anticipation across 
multiple generations. We anticipate that this information will inform research toward directing 
personalized therapies for these individuals. 
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2.0  LITERATURE REVIEW 
2.1 OVERVIEW OF IDIOPATHIC PULMONARY FIBROSIS 
Idiopathic pulmonary fibrosis (IPF) is the most common of several forms of interstitial 
lung disease (ILD). IPF ultimately leads to progressive breathlessness, respiratory failure, and 
death with a median survival of 4 years from the time of diagnosis.20 IPF is characterized 
histologically by the presence of the so-called usual interstitial pneumonia (UIP) pattern. UIP is 
part of the class of idiopathic interstitial pneumonias (IIPs). IIP’s are histologic patterns that are 
characterized by varying degrees of inflammation and fibrosis of the lung parenchyma, the portion 
of the lung functioning to maintain gas exchange.1 Other IIP’s include: nonspecific interstitial 
pneumonia (NSIP), cryptogenic organizing pneumonia (COP), acute interstitial pneumonia (AIP), 
respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), desquamative interstitial 
pneumonia (DIP), and lymphocytic interstitial pneumonia (LIP).1 The diagnosis of ILD is 
challenging as many of the forms of ILD have similar clinical presentations and overlapping 
histologic patterns on biopsy. Thus an accurate diagnosis is crucial for management and 
treatment.21 The American Thoracic Society and the European Respiratory Society have jointly 
published criteria used to establish the diagnosis of IPF. The diagnosis, based on the current 
consensus guidelines, requires the following: (1) exclusion of other known causes of ILD and (2) 
the presence of usual interstitial pneumonia (UIP) pattern by surgical lung biopsy. Alternatively, 
(3) patients may also be diagnosed with IPF without a surgical lung biopsy if the high-resolution 
computed tomography (HRCT) demonstrates the UIP pattern.20 
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The incidence (defined as the number of new cases per year) of IPF ranges from 4.6 per 
100,000 person-years to 17.43 per 100,000 person-years, as reported from the United States and 
the United Kingdom.22,23 Similarly, prevalence (the number of total cases per year) varies from 2.9 
per 100,000 to 63 per 100,000, reported from studies in Finland, the United States and Japan.22,24,25  
IPF predominantly occurs in individuals over the age of 60, with a median survival of 3-5 
years. The European IPF registry (erIPFreg) and insights-IPF registry in Germany have reported 
between 63% and 77% of patients are male.2,3 Individuals with IPF may present with a variety of 
symptoms. A study outlining characteristics of the European IPF registry (erIPFreg) documented 
around 90% presented with dyspnea, 70% with fatigue, and 50% with a dry cough.3 Upon 
examination, many individuals have “velcro-type” crackles, which has shown to be a predictor of 
UIP pattern on HRCT.26 Clubbing of the fingers has also been recorded in up to 50% of patients 
with IPF27. 
2.1.1 Pathogenesis 
The cause of IPF is not always known, though there are a number of environmental, 
occupational, and genetic risk factors which may contribute to the disease. In addition, up to 20% 
of cases of IPF are characterized as “familial,” meaning more than 2 first-degree relatives in the 
family have IPF.   
2.1.2 Treatment 
Management and treatment options are limited and consequently, the median survival of 
patients with IPF is 3-5 years. Along with IPF there are several co-morbidities which negatively 
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impact the prognosis, such as cardiovascular disease and diabetes.28 Medications can be taken to 
slow the rate of deterioration in the lung which may slow the progression of the disease, however 
they do not restore lung function already lost to fibrosis nor help alleviate symptoms for patients. 
The only cure for IPF is lung transplantation. However, the candidacy of these individuals 
choosing to undergo a single or double lung transplant is compromised with age and comorbidities.  
2.2 IPF RISK FACTORS 
There are a number of risk factors contributing to both the development of IPF and 
mortality from IPF. Smoking is considered one of the largest risk factors for IPF. Information 
collected from the EMPIRE Registry (European MultiPartner IPF Registry) found 53% of patients 
to be current or former smokers.29 A case-control study examining cigarette smoking as a risk 
factor for IPF found that those who had smoked at some point in their lives, including both current 
and former smokers, had a 60% increased risk for developing IPF.30 Finally, a retrospective study 
done by Karkkainen et. al, found current smokers to have a younger age of diagnosis than former 
or non-smokers, 58.1 versus 71.7, respectively.31 
2.2.1 Environmental 
Occupational and environmental exposures are also thought to be contributory toward the 
development of IPF. Such reported exposures include: asbestos, metal dusts, raising birds, wood 
dusts, solvents, and hairdressing.5,32,33 Although, pulmonary fibrosis due to asbestos exposure has 
its own diagnosis, asbestosis.34 A case-control study done in Egypt reported men working in the 
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chemical and wood-working industry had a higher risk for IPF.35 In addition, a study in Southern 
Europe found that farmers, vets, gardeners, and workers in the steel industry had an increased risk 
for IPF, this risk increased depending on the length of time with said exposure.36 
2.2.2 Genetics 
An often underappreciated risk factor for the development of pulmonary fibrosis is genetics 
and family history. Many studies have shown that patients who have a family history of pulmonary 
fibrosis, in parents or siblings, have a younger age of diagnosis than sporadic cases, or those 
without a family history.4,37 A case-control study done in Mexico at the National Institute of 
Respiratory Diseases found that 20% of patients with IPF had a parent or siblings also diagnosed 
with IPF.4 In Finland, a study was done to examine how many patients with a diagnosis of IPF 
also had a family member with a similar disease. The results from a questionnaire sent to IPF 
patients suggested that 88 of 675 (~13%) patients reported an affected family member.24 In 
addition, this study looked at medical records for 17 of these families and found that affected 
family members had an earlier age of onset compared to sporadic patients (61.9 years versus 65.3 
years, respectively).24 
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2.3 IPF PROGNOSTIC FACTORS 
2.3.1 Acute Exacerbations in IPF 
Many studies have attempted to elucidate acute exacerbations in IPF—episodes of rapid 
deterioration, which result in decreased pulmonary function and are frequently fatal.38 Acute 
exacerbations are seen more often in those with more advanced disease. There have been few 
therapeutic studies of acute exacerbations, and the field has struggled to define exactly what 
constitutes an acute exacerbation. A study by Collard et. al, proposed diagnostic criteria for acute 
exacerbations of IPF, of which are used by many clinical trials.39 Several studies have reported 
onset of acute exacerbations following a diagnostic procedure, such as a surgical lung biopsy or 
bronchoalveolar lavage. A retrospective study from January of 1990 to September of 2003 found 
23 of 147 patients with IPF were admitted to the hospital for acute exacerbation.40 Of those, 11 
met the proposed criteria for an acute exacerbation.40 Three of 11 patients developed acute 
exacerbation immediately following a surgical lung biopsy or bronchoalveolar lavage, five 
developed acute exacerbation 3-60 months following the diagnosis of IPF by surgical lung 
biopsy.40 Contrary to smoking being a perceived risk factor for IPF, Song et. al found that patients 
who had never smoked more often had acute exacerbations.38 This study additionally reported the 
median survival time after an acute exacerbation was 2.2. months.38 Intubation due to an acute 
exacerbation carries a nearly 100% mortality rate.41 
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2.3.2 Comorbidities in IPF 
 A number of comorbidities have also been shown to impact mortality rates on patients with 
IPF. The German INSIGHTS-IPF registry reported patients to have the following comorbidities: 
cardiovascular disease, diabetes, pulmonary hypertension, emphysema, and reflux.5 Other studies 
have also reported the incidence of lung cancer, sleep-related breathing disorders and 
psychological health concerns in patients with IPF.6-8 Many patients often present or develop 
multiple comorbidities, further impacting their mortality rate. A study examining a database of IPF 
patients found that close to 90% of patients had at least one comorbidity, with 30.5% having 
between 4 and 7 comorbidities.28 Of importance, this study found cardiovascular disease and lung 
cancer to have a statistically significant negative impact on survival, whereas GERD had a 
statistically significant positive impact on survival.28 A retrospective study done by Alakhras et. 
al at Mayo Clinic, evaluated a person’s BMI and mortality from IPF. Their study found that those 
with a higher BMI had increased survival compared to those with a lower BMI, a 91% 1-year 
survival rate as compared to 76% 1-year survival rate, respectively.42 
2.4  MANAGEMENT AND TREATMENT OF IPF 
Due to the severity and poor prognosis in IPF, management of the disease focuses on 
monitoring the course of IPF through pulmonary function tests. Treatment options remain limited 
and only serve to manage symptoms and slow the progression of lung fibrosis. The presence of 
multiple comorbidities can create additional challenges in the management of IPF since they can 
impact the progression of IPF.  
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2.4.1 Pulmonary Function Tests 
A number of tests are used to assess the severity of IPF. These tests are often done as a 
baseline test when a patient is diagnosed with IPF and further completed at regular intervals to 
measure and evaluate the disease course. These tests are also useful in monitoring response to 
therapies the patient may be undergoing.43 Physiologic measurements in IPF are those evaluating 
the function of the lung. A broad group of these tests is pulmonary function tests (PFT’s), most 
commonly tested are forced vital capacity (FVC), diffusing capacity of the lung for carbon 
monoxide (DLCO), total lung capacity (TLC), and alveolar-arterial oxygen difference in partial 
pressures (P(A-a)O2).20,44 FVC is the maximum amount of air exhaled following a maximal 
inhalation. Declines in FVC have been shown to be associated with increased mortality.45,46 A 
study of 179 patients with IIP found that at baseline, low levels of FVC, DLCO, PA02 were 
associated with a worse prognosis, particularly if the patient was an older male.46 While these 
PFT’s can be beneficial in assessing and helping to manage IPF, additional comorbidities impact 
the effectiveness of these tests on predicting disease course. FVC is the best measure at predicting 
prognosis in IPF.47 
2.4.2 Six-Minute Walk Test 
The six-minute walk test (6MWT) is another measurement taken in patients with IPF to 
assess the exercise capacity of the lung. This test is often used because it assesses the everyday 
activity level of the patient. It is employed clinically, especially in lung transplant to assess 
patient’s “readiness” for transplant.48,49 A double-blind placebo-controlled patient population from 
the INSPIRE trial found the 6MWT to be a predictor of mortality, such that those with a distance 
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<250 meters had a two-fold increased rate of mortality in a year.50 A study utilizing data from 
UNOS of individuals with IPF waiting for a lung transplant found that those with a 6MWT distance 
greater than 305 meters survived longer than those whose distance was less than 305 meters.51 The 
6MWT is also utilized in many clinical trials to assess the effectiveness of a medication or drug 
by comparing 6MWT distances before, during, and after use.49 Though the 6MWT is used in many 
studies, there are limitations to the interpretation due to confounding variables.9,10 
2.4.3 Pulmonary Rehabilitation 
In addition to lung function tests and pharmacologic management, pulmonary 
rehabilitation is often undertaken by many IPF patients. A study by Gaunaurd et al., compared 
patients with IPF undergoing a 3-month pulmonary rehabilitation program to patients with IPF 
with no organized exercise. The study found that pulmonary rehabilitation helped manage the 
symptoms brought on by the disease with consistent exercise, however this benefit did not continue 
long-term when regular exercise stopped.52 The management of symptoms in that study was 
assessed using the St George Respiratory Questionnaire for IPF (SGRQ-I), which showed that 
changes in the score reflected positively on an improvement in quality of life.52 
2.4.4 Medications 
There are currently two FDA-approved drugs for the treatment of IPF: pirfenidone and 
nintedanib. These were approved in October of 2014 and are antifibrotic agents. Prior to their 
approval, two randomized CAPACITY trials (004 and 006) were used to confirm that pirfenidone 
reduced lung deterioration, as shown from the Phase 2 study. The study assessed the efficacy of 
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pirfenidone through evaluating FVC. Study 004 found a reduced decline in FVC in those taking 
pirfendione compared to the placebo group after 72 weeks.11 Post-approval, another study used 
data from the CAPACITY and ASCEND trials to compare survival (in years) when using 
pirfenidone versus supportive care (i.e. supplemental oxygen, pulmonary rehab, etc.). Their results 
showed approximately a two-and-a-half-year increase in survival with pirfenidone compared to 
supportive care.12 The efficacy of nintedanib has also been shown through a reduction in decline 
of FVC. Patients who completed the Phase III INPULSIS trial were eligible for the open-label 
INPULSIS extension comparing nintedanib versus a placebo. The study compared those with 
>50% and <50% predicted FVC at the start of the study and the results showed both had a similar 
decline in FVC.53 Patients with <50% predicted FVC have significant deterioration to the lungs, 
however these results showed nintedanib is beneficial despite how significant the presence of lung 
damage.53  
2.4.5 Supplemental Oxygen  
Many patients have disease progression requiring the use of supplemental oxygen to 
improve quality of life in daily activities. Supplemental oxygen helps alleviate dyspnea and 
hypoxia.54 Much research on the use of oxygen in patients with interstitial lung diseases is 
extrapolated from studies involving COPD. Although, a retrospective study was done comparing 
use of oxygen in COPD and ILD by measuring the change in oxygen saturation (SpO2) throughout 
the 6MWT. The results showed ILD patients had a larger change in oxygen saturation and lower 
levels of SpO2, suggesting data from COPD patients may not be as applicable as previously 
thought.55 A number of studies and surveys have been conducted to better understand patient 
perceptions and challenges of using supplemental oxygen. Data from these studies have shown 
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many individuals experience (or are afraid of experiencing) issues with malfunctioning equipment 
and difficulty traveling with supplemental oxygen54,56,57. In addition, many individuals describe 
the psychosocial impact of being on oxygen, particularly in feeling stigmatized for needing 
supplemental oxygen, as well as being unable to hide their illness.54 Overall, supplemental oxygen 
provides many benefits to patients and improves their quality of life, with some unfortunate 
drawbacks.  
2.4.6 Quality of Life in IPF 
Given the poor prognosis in IPF, assessing a patient’s quality of life and mental health is 
an important area of investigation. A number of studies have assessed patients’ quality of life 
through health-related quality of life (HRQL) surveys.58,59 Swirgris et al., developed an IPF 
specific HRQL, called a tool to assess quality of life in IPF (ATAQ-IPF).60 This survey 
incorporates results from the 6MWT and PFT testing as well as results on over 200 questions. 
These questions incorporate information from all aspects of their life and are organized into 
domains. These domains range from symptoms to finances and relationships.60 In assessing the 
answers to questions in the study sample, results found a significant correlation in HRQL with 
measures of FVC%, DLCO%, and 6MWD for eight, nine, and five the 13 domains.60 There was 
also significantly greater ATAQ-IPF scores in nine of the 13 domains for patients who required 
supplemental oxygen compared to those who do not.60 Data from an Australian IPF registry 
utilized the SGRQ to assess quality of life in IPF. They found that dyspnea, cough, and depression 
most significantly contributed to the quality of life in IPF.61  
 14 
2.4.7 Lung Transplant 
For some patients with IPF, lung transplants may be a treatment option as a means to extend 
their lifespan. The International Society for Heart and Lung Transplantation has specific guidelines 
for listing a patient for lung transplantation with IPF. They are as following: histologic or 
radiographic evidence of UIP and any of the following: A DLCO <39% predicted, a 10% or greater 
decrement in FVC during 6 months of follow up, a decrease in pulse oximetry <88% during a 6-
minute walk test and honeycombing on HRCT (fibrosis score >2).48 Ultimately, deciding to be 
listed for a lung transplant also relies on other factors, such as quality of life, projected clinical 
course, and risks of lung transplantation.48 Data from The Registry of the International Society for 
Heart and Lung Transplantation reports that from January of 1995 to June of 2011 23.2% of all 
lung transplants were done due to IPF, accounting for the second highest number of lung 
transplants, second to COPD and emphysema.62 Of those done for IPF, about 56% were single 
lung transplants and 44% were double lung transplants.62 A retrospective study done to assess 
survival in patients receiving either a single lung transplant or double lung transplant for IPF found 
that survival was better in double lung transplants than single lung transplants, 8.34 years versus 
7.37 years, respectfully.63 One study aimed at comparing survival time following a lung transplant 
compared to remaining on the wait list. This study found that despite the high risk of mortality 
immediately following a lung transplant, after one year the survival rate post-transplant was better 
than remaining on the wait list.64 Several limitations from that study should be considered, in that 
everyone on the wait list and those who received transplants were likely not equally as healthy or 
unhealthy. Many individuals with IPF have a number of comorbidities which affect the prognosis. 
In addition, quantifying any gained longevity following a lung transplant is difficult due to a 
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myriad of factors. Further complicating prognosis following a lung transplant is certain genetic 
factors mediating the disease progression (discussed in the next section). 
2.5 GENETICS OF IPF 
Genetics is thought to play a large role in pulmonary fibrosis with studies reporting up to 
20% of cases of IPF having a family history of lung disease.65 Familial pulmonary fibrosis, which 
is used to describe those with two or more family members with pulmonary fibrosis, provides clues 
for the genetic underpinnings of IPF. A twin study case report from 1950 reported monozygotic 
twins who both developed IPF close to the age of 50 and had not lived together since childhood, 
thus reducing the likelihood of shared environmental exposures significantly impacting the 
occurrence of IPF.66 Although many genes have been implicated in familial IPF, the mechanism 
behind the disease most commonly involves the telomeres and telomeric shortening. Many of these 
implicated genes exhibit autosomal dominant inheritance, often consistent with genetic 
anticipation. 
2.5.1 Genes and Inheritance of IPF 
Both rare and common variants have been identified through family studies in sporadic and 
familial IPF. Rare variants are defined as those with a minor allele frequency less than 0.1%, 
common variants are those with minor allele frequency >5%. Rare variants have been identified 
in genes in the telomere pathway (TERT, TERC, DKC1, TINF2, RTEL1, NAF1 and PARN) and in 
surfactant production (SFTPC, SFTPA1, SFTPA2, and ABCA3).67-69 Common variants have also 
 16 
been associated with familial and sporadic IPF, although the pathogenic mechanism is unknown 
and their usefulness in the clinic is limited by their high allele frequency. The most significant 
common variant is found in the promoter of MUC5B.70 Additional variants have been identified 
in TERT, TERC, and OBCF1.71  
The inheritance of pulmonary fibrosis is not clearly established, though most family 
histories tend to show an autosomal dominant mode of inheritance. Autosomal recessive and x-
linked inheritance have also been suggested. A study of 111 families with pulmonary fibrosis 
conducted by Steele et al., at three sites in the United States, found the pedigrees supported an 
autosomal dominant mode of inheritance.72 Further, segregation in 30 families reported by 
Marshall et al., in the United Kingdom supported an autosomal dominant mode of inheritance, 
although autosomal recessive could not be ruled out without further genetic testing.37  
One of the genes implicated in IPF is DKC1, a gene located on the X chromosome, and is 
consistent with x-linked inheritance. In addition to causing IPF, pathogenic variants in DKC1 can 
cause Dyskeratosis Congenita (DC), a childhood onset disorder characterized by oral leukoplakia, 
nail dystrophy, and hyperpigmentation of the skin.73 In addition, those with DC often have bone 
marrow failure, pulmonary fibrosis, and increased cancer risks.73 Other genes have also been 
implicated in DC, resulting in autosomal dominant and autosomal recessive inheritance. 
Pathogenic variants in hTR (TERC) have been associated with autosomal dominant DC, as shown 
by three pedigrees reported in a study done at Hammersmith Hospital in Iowa.74 It is thought that 
x-linked DC is more severe and onset is earlier than in autosomal dominant DC.75 Mechanistically, 
this is because DKC1 binds to hTR and is necessary for stability and telomerase synthesis, thus, 
patients with pathogenic variants in DKC1 have lower levels of hTR resulting in insufficient 
telomerase to maintain the length of telomeres.76 
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2.5.2 Telomeres 
Telomeres are structures located at the ends of chromosomes, made up of repeated DNA 
sequences. In humans, the telomere DNA is 2-20 kb long, with repeats of the sequence 
TTAGGG.77 Telomeres provide several functions in cells, but their primary role is suppressing a 
DNA damage response and subsequent end-to-end fusion. Telomeres shorten each time a cell 
replicates. The “end-replication problem”, a term coined by Watson in 1972, exists because there 
is a 3’ overhang of single stranded telomeric DNA on the lagging strand, which cannot be 
completely synthesized by DNA polymerase.78 Incomplete synthesis of the 3’ end of DNA leads 
to shortening of the chromosome during the following round of replication. To circumvent this, an 
enzyme, telomerase, provides the de novo addition of nucleotides to the ends of chromosomes to 
allow replication to proceed to the end of the chromosome. Telomerase is an RNA-dependent 
DNA polymerase composed of human telomerase RNA (hTR, also known as TERC) and human 
telomerase reverse transcriptase (hTERT). These components allow for replication of the telomere 
DNA on the 3’ end by using hTR as the template and hTERT to reverse-transcribe the sequence.79 
Telomerase and the shelterin complex, a complex of 6 proteins that coat the telomere, control the 
length of telomeric DNA. The shelterin complex includes the following proteins: TRF1, TRF2, 
POT1, RAP1, TIN2 and TPP1.80 TRF1 and TRF2 bind to the double stranded TTAGGG repeats 
to inhibit telomere elongation through recruitment of the other 4 proteins in the shelterin 
complex.81 POT1 binds single-stranded telomeric DNA and is regulated by TPP182. TIN2 can bind 
both TRF1 and TRF2, while RAP1 is recruited by TRF2.82,83 
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2.5.3 Short Telomeres in IPF 
Although a number of pathogenic variants have been implicated in the telomere pathway, 
it is the resulting telomere shortening that appears to be the primary contributor to the 
manifestations of the disease. A study examining familial and sporadic IPF stratified individuals 
whom had a TERT or TERC pathogenic variant. Telomeres were <10th percentile in all probands 
who had a TERT or TERC pathogenic variant.84 Of those with no pathogenic variants, telomeres 
<10th percentile were found in 25% and 37% of individuals with sporadic and familial IPF, 
respectively.84 Another study utilized probands and their family members enrolled in the 
Vanderbilt Familial Pulmonary Fibrosis Registry and found that affected individuals who have a 
pathogenic variant in a telomerase also had significantly shorter telomeres than asymptomatic 
carriers of the same pathogenic variant.17 In this study, asymptomatic carriers were about 11 years 
younger than the probands at their time of diagnosis, which is consistent with the mechanism of 
shorter telomeres driving disease.17  
A further sequalae of telomere-mediated IPF is significant co-morbidities, due to the 
shortening. Bone-marrow failure can manifest in patients with IPF, or separately in individuals 
who have short telomeres. Pathogenic variants in TERT and TERC have been found in patients 
with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).85,86 These were found 
in patients lacking the characteristic skin findings of Dyskeratosis Congenita (DC), given DC is a 
bone-marrow failure syndrome as well. An additional co-morbidity previously established in 
telomere-mediated disease is gastrointestinal concerns. A sample of 38 individuals ranging in age 
from 15 months to 34 years found that 16% had an evaluation by a gastroenterologist. In these six 
individuals, four had pathogenic variants in DKC1, TERT, or TR.87 Presentations varied in these 
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individuals, some had difficulty swallowing, esophageal stenosis, abdominal pain, and a 
colectomy.87 
2.5.4 Anticipation in telomere-mediated disease 
One of the strongest observations linking telomere length to disease pathogenesis is the 
occurrence of genetic anticipation in families with variants in telomere-maintenance genes. 
Genetic anticipation occurs when successive generations have earlier ages of onset of disease and 
have a more severe presentation. This was identified in a study of eight families with TERC 
pathogenic variants in which parents were affected with symptoms of DC between 36 and 61 years 
of age, whereas their children showed symptoms around 14.5 years of age.18 Telomere length of 
these individuals was studied to assess if that contributed to the anticipation, and it was found that 
children had statistically significant shorter telomere length than their parents indicating that 
shortened telomere length may contribute to anticipation.18 Telomere-mediated disease provides 
the only example of genetic anticipation in which the disease phenotype can change in each 
subsequent generation.88 In a family with a known TERT pathogenic variant, a pedigree analysis 
showed genetic anticipation in the family. In this three-generation pedigree, it was found that 
individuals in subsequent generations developed premature graying at younger ages (age 20’s vs 
age 9), liver and lung fibrosis, and aplastic anemia.19  
2.5.5 Lung transplants and telomeres 
Lung transplant is the only clear life-extending therapy for patients with IPF. However, 
recent data suggest that post-transplant complications may arise due to shortened telomere length 
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or the presence of a pathogenic variant implicated in IPF.13-15 An observational cohort study 
followed 82 individuals pre- and post-lung transplant who were divided into two groups based on 
telomere length. A total of 26 individuals had telomere length <10th percentile and 56 individuals 
had telomere length >10th percentile.13 This study found that the rate of death was higher in 
individuals with telomere length <10th percentile (54% vs 18%).13 In addition to decreased survival 
time, these individuals also had an increased risk of infections and higher rates of allograft 
dysfunction.13 Eight subjects with telomerase pathogenic variants were evaluated for post-
transplant outcomes through a study conducted at Johns Hopkins. The results from this study 
described that patients with telomerase pathogenic variants are at a higher likelihood of having 
post-transplant complications such as: minimal/moderate rejection, infectious complications, 
hematologic complications, and medication-related toxicities.14 A recent study conducted on lung 
transplant recipients at the University of Pittsburgh and Johns Hopkins found that recipients with 
short telomeres have an increased risk for CMV infection—a very serious complication of lung 
transplant and a major risk for chronic allograft dysfunction (CLAD).15 Ultimately, data from this 
study and others has suggested telomere length may be useful in stratifying post-transplant risks 
for patients as well as helping to personalize their treatment.15 
2.5.6 Current Understanding of the Use of Genetic Information 
Currently, and despite the significant evidence supporting a role for genetics in the 
pathogenesis of disease, there are no guidelines regarding genetic testing in patients with 
pulmonary fibrosis.20 The majority of the knowledge generated regarding the genetics is from 
research studies, which are often through active efforts aimed at better characterizing this disease 
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through the collaboration of many large centers. Despite this, cohorts of family member 
participation are small, making the characterization of rare variants difficult. 
Historically, physicians who treat patients with IPF have never considered the impact of 
genetics on decision-making for treatment options because the results were not “actionable.” That 
is, patients with clearly familial disease were treated the same as patients with so-called “sporadic” 
disease. In fact, many IPF providers would pursue a “Don’t ask, don’t tell” policy, since genetics 
could negatively impact a decision for transplant.89 However, given the insight provided from 
genetic studies, a clinical shift is happening to personalize care for patients through precision 
medicine initiatives. This is quite evident for patients undergoing lung transplants. As mentioned 
in the preceding subsection (2.4.5), there are poor outcomes post-transplant for patients with short 
telomeres or pathogenic variants in telomere-related genes.13-15 The evidence from these studies 
indicate that bone marrow failure following lung transplant, probably the consequence of anti-
rejection toxicity on particularly vulnerable hematopoietic cells with short telomeres, is to blame 
for the poor outcomes of these patients following transplant.13-15 A proof-of-concept trial is 
currently underway at the University of Pittsburgh Medical Center (UPMC) to address the risk of 
bone marrow failure following lung transplant for patients with short telomere pulmonary fibrosis. 
The treatment will include lung transplant followed by allogeneic bone marrow transplant from 
the donor at 4 months following the transplant.90 The bone marrow will then recognize the lung as 
self and may allow for significant reduction or even elimination of the anti-rejection meds in these 
patients. Patients have had success with this new protocol who have end-stage lung disease.91  
Furthermore, researchers have mentioned the importance of referring early for lung 
transplants, as historically patients were in their 70’s, and now many centers do not perform lung 
transplants in patients who are older due to the increased risk for comorbidities in these 
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patients.92,93 One study argued that patients who have short telomeres should be identified for 
earlier transplant evaluation.93 The preference for many centers and physicians is to transplant 
younger individuals, as they are considered healthier and likely have less comorbidities. It is 
possible that the younger patients with pulmonary fibrosis who are more often referred for lung 
transplant, may be the population enriched with short telomeres. Not only because they may have 
been clinically tested for short telomeres and referred earlier as studies suggest, but also because 
patients who have shorter telomeres or pathogenic variants develop the disease at a younger age. 
Overall, this suggests that genetic testing and measurement of telomere length may be particularly 
important in this population in the context of lung transplant.  
As telomere length and genetic variants in pulmonary fibrosis now appear, based on high 
quality evidence, to impact the clinical outcomes of patients, especially following transplant, it is 
clear that genetic testing may have a role in the assessment of patients. This does, of course, come 
with several caveats: first, genetic testing can potentially bias providers away from a potentially 
life-saving transplant. Second, similar to at-risk patients for non-curable diseases such as 
Huntington’s disease, genetic testing needs to be considered very carefully in this population. Such 
information can cause significant psychosocial sequelae in young people and may be used to deny 
coverage for insurance. Clinical genetic testing in pulmonary fibrosis is in its infancy. All these 
issues need to be considered very carefully as the field evolves and genetic information becomes 
a standard of care in patients.  
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3.0  MANUSCRIPT 
3.1 BACKGROUND 
Idiopathic pulmonary fibrosis (IPF) is a form of interstitial lung disease (ILD) 
characterized by dyspnea, and histologically, by the presence of usual interstitial pneumonia 
pattern.1 This progressive lung disease ultimately leads to respiratory failure in the sixth or seventh 
decade of life.2,3 Following a diagnosis, the median survival is 3-5 years due to the limited 
management and treatment options. The term idiopathic is used due to the unknown cause of IPF, 
although a number of risk factors and genetic changes contribute toward the risk of IPF. 
3.1.1 Risk Factors 
A number of environmental, occupational, and genetic risk factors have been identified in 
IPF. Of these factors, smoking is considered to be the largest preventable risk factor. Many studies 
suggest more than 50% of patients with IPF are current or former smokers.29,30 Environmental and 
occupation exposures have also been established, though the empirical risk, while not as well 
quantified, is thought to be increased with longer exposure times.5,32,33,36 Lastly, the role of genetics 
is rapidly evolving. Around 20% of individuals report a family history of IPF.4,37 These individuals 
have what is considered “familial” IPF, meaning they have one or more affected first-degree 
relatives.  
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3.1.2 Prognostic Factors 
Further complicating the disease course in IPF are acute exacerbations and comorbidities. 
Acute exacerbations are episodes of rapid deterioration often following a diagnostic procedure, 
which ultimately result in decreased survival time.38,40 For many individuals, comorbidities may 
have a negative impact on survival, such as cardiovascular disease and lung cancer.5-8 Almost all 
patients report at least one comorbidity, though many report numerous.28 In addition to the impact 
comorbidities have on survival, they also result in challenges related to managing IPF symptoms 
and predicting disease course.28,42 
3.1.3 Management 
The disease course of IPF is often monitored through a variety of pulmonary function tests. 
Two in particular, forced vital capacity (FVC) and the six-minute walk test (6MWT), are 
commonly used in clinical trials and research studies as a means to determine the effectiveness of 
an intervention.20,43,44 Although, the effectiveness of these measures is unclear due to the presence 
of confounding variables in many situations.9,10 
Pulmonary rehabilitation, supplemental oxygen, and medications are interventions used to 
mediate the disease course of pulmonary fibrosis. Pirfenidone and Nintedanib are two FDA-
approved drugs which may help slow the progression of lung fibrosis, but do not restore lung 
function lost to fibrosis or increase lifespan.11,12,53 These medications additionally have a myriad 
of side effects and do not help patients with the symptoms associated with IPF. Other patients 
choose to undergo a single or double lung transplant to extend their lifespan.62,63 Co-morbidities 
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and genetic factors complicate the indications and prognosis for a lung transplant (discussed in 
section 3.1.4.1) 
3.1.4 Genetics of IPF 
In many familial IPF cases, as well as some sporadic cases, pathogenic variants in genes 
have been identified. These genes are located in the telomere maintenance or surfactant pathways. 
In the telomere maintenance pathway, the mechanism behind genetic pathogenic variants is 
thought to be well-understood, in that the shortening of telomeres is the driver of the disease.17 
Telomeres are located at the ends of chromosomes and are maintained by telomerase, composed 
of telomerase RNA (hTR) and telomerase reverse transcriptase (hTERT), which catalyzes de novo 
addition of telomere DNA to prevent loss of essential DNA.79 The majority of genes implicated in 
IPF have been shown to have autosomal dominant inheritance.72 The shortening of telomeres 
appears to be associated with the genetic anticipation seen with IPF.18 As telomeres shorten in each 
successive generation, there is earlier age of onset of disease as well as changes in presentation of 
the disease.18 For example, younger generations may have premature graying, liver fibrosis, and 
aplastic anemia, which may not be something older generations of the family manifest.19 In 
addition to genetic anticipation, there are further co-morbidities associated with telomere-mediated 
IPF. Other bone-marrow failure disease, such as Myelodysplastic Syndrome (MDS) or Acute 
Myeloid Leukemia (AML) have been found in patients with short telomeres, as well as patients 
with pathogenic variants in TERT and TERC.86,87 In addition, gastrointestinal concerns have been 
reported in patients with short telomeres, including esophageal stenosis and dysphagia.87 
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3.1.4.1 Complications of IPF Genetics in Lung Transplant 
 
Perhaps one of the most important implications of genetic findings is in those patients 
considering a lung transplant. Patients who have shortened telomeres (<10th percentile) or a 
pathogenic variant in the telomere pathway are at risk for a number of post-transplant 
complications.13 Such complications may include an increased chance of rejection, infections, 
hematologic complications, CMV infections, and other clinical morbidities.13-15 Knowing a 
patient’s telomere length and genetic status may help personalize treatment, particularly in 
assessing the risk for post-transplant complications.15 
3.1.5 Goals of the Study 
Currently, the clinical guidelines set forth by the American Thoracic Society do not have 
recommendations that genetic testing be undertaken in any patient with IPF. Given the important 
implications this knowledge may have on a patient’s treatment and outcome, this goal of this study 
is to better understand and characterize genetic variants in IPF and their segregation in families. 
Clinical information from the patient and the family history were ascertained. A blood sample was 
obtained from the proband for whole genome sequencing (WGS). The WGS data was analyzed 
for rare variants in genes implicated in the telomere or surfactant pathway. In addition, samples 
from affected and unaffected family members were obtained from those willing and able to test 
for segregation of rare variants in families.  
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3.2 METHODS 
3.2.1 Study Population 
The study population included individuals who were treated for pulmonary fibrosis at the 
Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease. This project was 
approved under two different Institutional Review Board protocols: the Genomics and Proteomics 
of Idiopathic Pulmonary Fibrosis (GAP) Study and the Familial IPF Genetics Study. For the GAP 
study, clinical history was extracted from the participant’s medical chart. Participants were eligible 
for the genetic study if their lung disease was suggestive of familial IPF and noted by their 
physician in their medical chart. For the familial IPF genetic study, the proband was consented and 
a pedigree was taken. In the event the proband was unavailable, a pedigree was constructed from 
information obtained from their medical records. To facilitate family member participation, 
probands were given a family letter that they could distribute to their family members who may 
be interested in participating in the study. Because of the high mortality of this disease, patients 
who were previously consented are still included in this study even if they are now deceased. For 
these individuals, pedigrees were ascertained via medical record review. 
3.2.2 Whole Genome Sequencing and Variant Classification. 
Whole genome sequencing was carried out at the University of Pittsburgh Medical Center 
Genome Center on blood obtained from the proband from each family. For sequencing, Illumina 
150 bp paired-end sequencing on NovaSeq 6000 was done with an average coverage of 25x across 
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the entire genome. This CLIA certified sequencing center utilizes the DRAGEN Germline V2 
Pipeline for initial read alignment and variant calls.  
A variant call file (VCF) of every variant in each individual was generated. Variants of 
interest were mapped using the NCBI RefSeq coordinates using ANNOVAR (December 2018), 
and allele frequencies from various populations were extracted from gnomAD 
(https://gnomad.broadinstitute.org, December 2018) in addition to medically relevant variants and 
their phenotypes as reported in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/, December 2018). 
Variants from the genes associated with interstitial lung disease or telomere biology were 
extracted and annotated including 1000 bp 5′ and 3′ of the transcriptional start and stop sites, 
respectively. These were: TERT, TERC, RTEL1, PARN, TINF2, NAF1, DKC1, CTC1, OBCF1, 
TEN1, SFTPC1, SFTPA1, SFTPA2, and ABCA3. Analysis focused on coding variants or variants 
proximal to the splice donor or acceptor sites.  
3.2.3 Sanger Sequence Confirmation 
Each potential variant identified in WGS was confirmed by PCR amplification using 
oligonucleotides flanking the exon containing the variant of interest (see Table 1). PCR amplicons 
were purified over silica columns and sent for Sanger sequencing and Genewiz (South Plainfield, 
NJ). Sequence traces were aligned using Sequencher or SnapGene. PCR was carried out using 
phusion polymerase with 50ng template DNA under standard conditions. Some PCRs included 
1 M Betaine has a PCR adjuvant. 
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Table 1. TERT and RTEL1 forward and reverse primers 
 
3.2.4 Pedigree Ascertainment 
Pedigrees were ascertained from probands who consented and were able to provide family 
history information. Pedigrees were drawn using standard nomenclature, as outlined by the 
National Society of Genetic Counselors.94 A number of questions were asked of the proband, as 
stated in the Interview Guide for Pedigree (Appendix B). Pedigrees are not provided in this 
document to preserve confidentiality. The author may be contacted for further information 
regarding the information contained in the pedigrees (Appendix C). 
3.2.5 Protein Alignment 
Amino acid sequences from the corresponding RefSeq genes were obtained from the NCBI 
(https://www.ncbi.nlm.nih.gov, February 2019) and aligned using Clustal Omega 
(https://www.ebi.ac.uk/Tools/msa/clustalo/, February 2019). 
Gene Forward Primer Reverse Primer 
TERT 5’ -GCATTCATGCACGCACACAGGCAC- 3’ 3’ – CACTCACTCAGGCCTCAGACTC- 5’ 
RTEL1 5’ -GGCAGGATGGGAGTTTCCTG- 3’ 3’ -CCGCCAGAGAACCAAAGTGA- 5’ 
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3.3 RESULTS 
The participants in this study were six patients diagnosed with IPF. These patients were 
known to have familial disease or concurrent hematologic malignancies. Four of the patients have 
results back from whole genome sequencing (WGS), two patients have results pending however, 
their pedigrees have been analyzed given the classical presentation of familial IPF. The results 
from WGS were filtered to variants with <1% allele frequency in the gnomAD database. Further, 
the results were analyzed for non-synonymous exonic variants in the genes listed in section 3.2.2. 
If no non-synonymous exonic variants were found, then rare intronic variants were examined in 
the genes listed in section 3.2.2. The results from the six patients are described in the following 
subsections. 
3.3.1 Patient 1 
Patient 1 is a deceased 83-year-old female, diagnosed with IPF at the age of 78. She had a 
history of smoking. A pedigree was ascertained from her medical chart and of her five siblings, 
one had a diagnosis of IPF and another had a myeloproliferative disorder. Results from WGS found 
no rare exonic variants in the genes evaluated. 
3.3.2 Patient 2 
Patient 2 is a male in his early 70’s, diagnosed with familial IPF three years prior. He was 
a former smoker and reported a number of environmental exposures. A pedigree was collected 
from the patient which describes a sibling with IPF, their mother had emphysema and lung cancer. 
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 Results from WGS for this patient found no rare exonic variants. This patient did have an 
intronic variant in DKC1, with an allele frequency of 0.0003 (7 of 10,655 sequenced individuals) 
(https://gnomad.broadinstitute.org, April 15, 2019). This intronic variant is located 1,025 bases 
upstream of the second exon. 
3.3.3 Patient 3 
Patient 3 is a deceased, 67-year-old male with a complex medical history of idiopathic 
pulmonary fibrosis (IPF) and a myelodysplastic syndrome (MDS). He was diagnosed with IPF one 
year prior to his death when a CT scan showed usual interstitial pneumonia. Pathology showed 
atypical adenomatous hyperplasia which can increase the risk of lung cancer in patients with IPF.  
At age 67, he was diagnosed with an MDS. A bone marrow chromosome analysis showed a 
complex karyotype consisting of numerous numerical and structural abnormalities. Double minute 
chromosomes and heterogenous staining regions are present, indicating gene amplification has 
likely occurred. This karyotype also confirmed the MDS was transforming to AML. Additional 
information in his medical record indicated he had exposures of asbestos, benzene, lead, radiation, 
and petroleum products due to his occupation. No family history of the disease was identified. 
 Results from WGS for this patient identified a rare exonic variant in RTEL1. The variant 
has an allele frequency of 0.0005 (76 carriers of 139,870 sequenced individuals) 
(https://gnomad.broadinstitute.org, April 15, 2019). This coding DNA change, 
RTEL1(NM_001283009.1):c.1955T>C, was confirmed via Sanger sequencing. The trace 
generated from SnapGene is shown in Figure 1, which shows the patient is heterozygous for this 
change. The amino acid change is RTEL1(NP_001269938.1):p.M652T. Methionine (M) is a non-
polar amino acid, and threonine (T) is a polar amino acid. By using the UCSC Genome Browser 
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track “Vertebrate Multiz Alignment & Conservation (100 Species)”, this amino acid is relatively 
well conserved down to fish, with a few exceptions (https://genome.ucsc.edu/cgi-bin/hgGateway, 
April 15, 2019). As shown in Figure 2, one of those exceptions is in chicken, where the amino acid 
is tryptophan. However, tryptophan (W) is also a non-polar amino acid like methionine. This 
variant has not been reported in the literature. Though, it has been reported by a lab on ClinVar. 
With a two-star rating, this was classified as a variant of uncertain significance (VUS). 
 
 
 
 
 
 
 
 
Figure 1. RTEL1 Trace 
 
Figure 2. RTEL1 ClustalW Alignment 
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3.3.4  Patient 4 
Patient 4 is a male in his late 60’s, diagnosed with familial idiopathic pulmonary fibrosis 
(IPF) one year ago. His medical history is notable for GERD. In addition, he reported a number of 
exposures, including chemicals, fertilizers, and asbestos. A pedigree was collected and shows the 
proband had a sibling with IPF who underwent lung transplantation. 
Results from WGS for this patient identified a rare exonic variant in TERT. The variant has 
an allele frequency of 0.0004 (48 carriers of 140,174 sequenced individuals) 
(https://gnomad.broadinstitute.org, April 15, 2019). The coding DNA change, 
TERT(NM_198253.2):c.3257G>A was confirmed via Sanger sequencing. The trace generated 
from SnapGene for this variant, shown in Figure 3, confirms the patient is heterozygous for this 
change. The amino acid change is TERT(NP_937983.2):p.R1086H. Arginine (R) and histidine (H) 
are both non-polar positive amino acids. By using the UCSC Genome Browser track “Vertebrate 
Multiz Alignment & Conservation (100 Species)”, this amino acid is not well conserved 
(https://genome.ucsc.edu/cgi-bin/hgGateway, April 15, 2019). Figure 4 shows a sample of species, 
exhibiting the poor conservation. Serine (S), as in mouse and rat, is a polar amino acid. Lysine (K) 
is a non-polar positive amino acid as well. Although this amino acid is not conserved through many 
species, a different change has been reported in the literature at this base (p.R1086C) for an 
individual with usual interstitial pneumonia with connective tissue disease.16 
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Figure 3. TERT Trace 
 
Figure 4. TERT ClustalW Alignment 
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3.3.5 Patient 5  
Patient 5 is a woman in her 60’s who has several siblings that have been diagnosed with 
IPF. A pedigree was collected and shows a number of autoimmune comorbidities amongst the 
siblings. A parent also had a diagnosis of IPF.  
Whole genome sequencing is currently pending for individuals in this family. 
3.3.6 Patient 6 
 Patient 6 is a woman diagnosed with IPF in her 50’s who has had IPF for three years. A 
pedigree was collected, one sibling has an autoimmune disease. Another sibling has IPF with 
additional comorbidities, some of which include COPD and cancer. Lung cancer is also prevalent 
in older generations of family members. 
 Whole genome sequencing is currently pending for this individual. 
3.4 DISCUSSION 
In this study, we characterized a small sample of sporadic and familial IPF probands in 
hopes of characterizing genes implicated in IPF. In turn, this characterization will help us better 
understand the genetics of IPF and how this information may impact patients, their family 
members, and their course of treatment. Whole genome sequencing was undertaken in these 
individuals with sporadic and familial IPF. The results for this small cohort of patients identified 
a rare RTEL1 variant in a patient with sporadic IPF and MDS, and a rare TERT variant in a patient 
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with familial IPF. Two familial IPF patients were found to have no rare, exonic variants in genes 
previously associated with telomere or surfactant biology. These results do not rule out that there 
is not a genetic cause for those two familial IPF patients, as it is possible they have a rare variant 
in a gene not yet known to be associated with IPF. An alternative cause for those patients could be 
shared environmental factors between the siblings leading to the disease.  
RTEL1 and TERT are genes known to be implicated in IPF. RTEL1 was first implicated in 
Dyskeratosis Congenita and autosomal recessive Hoyeraal-Hreidarsson Syndrome (HS), a severe 
bone-marrow failure syndrome, but has since been implicated in a number of familial IPF 
kindreds.95-97 As in Patient 3, who has an RTEL1 variant, recent studies have shown an association 
between RTEL1 pathogenic variants in patients with bone marrow failure, though this association 
is premature and not well defined.98,99 All of these syndromes are characterized by short telomeres, 
leading to the disease phenotype. This is because RTEL1 encodes a helicase and functions to 
unwind the secondary structure of DNA at the telomere.100 Similarly, pathogenic variants in TERT 
cause shortening of the telomeres. TERT encodes a reverse transcriptase and is important for 
extending the telomeres using an RNA template. In both of these genes, through different 
mechanisms, we see shortened telomeres which drive the clinical phenotype of IPF. 
These results further support the difficulty in characterizing the genetics of the disease, 
particularly in identifying variants in both familial and sporadic patients. In addition, tests of 
segregation or functional assays are necessary to determine the pathogenicity of identified variants. 
Currently, only functional assays exist for TERT and TERC. There is no functional assay for 
RTEL1101, so in this study, tests of segregation would be recommended in Patient 3, who had a 
variant in RTEL1. However, the majority of this patient population is in their sixth or seventh 
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decade of life, meaning many of the patients’ parents and even siblings are deceased. This makes 
it difficult to test for segregation in these families.  
Using whole genome sequencing was an effective approach in analyzing the genetics of 
IPF for this study given its decreasing cost. This test can identify rare variants in both intronic, 
exonic, and splice variants which could result in this disease. In addition, this test will enable us 
to possibly identify new genes associated with IPF, for those individuals whom a rare variant was 
not identified. This would not be possible if a panel test was used, as that test would only look for 
genes currently associated with IPF and would not look for intronic or splice variants.  
As more research better elucidates the genetic underpinnings of this disease and testing 
continues to enter the clinical arena, it will be imperative to have a plan in place to discuss genetic 
testing and this disease with patients and families. This disease does have incomplete penetrance, 
and variable manifestations because of genetic anticipation due to the shortening of telomeres.102 
Given all of these aspects, ethical questions arise as to whether to test asymptomatic relatives. 
Even if a relative is found to carry a pathogenic variant, there are currently no guidelines 
recommending any surveillance or management. Additionally, a person who carries a pathogenic 
variant may not develop this disease due to incomplete penetrance.18 On the other hand, in patients 
with short telomeres we may see genetic anticipation in families, meaning subsequent generations 
are manifesting extra-pulmonary symptoms, which may be more severe, and at earlier ages.18,19 
Lastly, identification of a pathogenic variant associated with shortened telomeres has implications 
for management outcomes, thus this information may be beneficial for precision medicine 
initiatives. 
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3.4.1 Study Limitations 
In this study, a limitation is the size. This cohort only included six probands with sporadic 
or familial disease who underwent WGS to look for rare variants in the telomere or surfactant 
pathway. This sample size is not representative of all patients with either sporadic or familial 
disease.  
3.4.2 Future Directions 
In subsequent studies, it will be important to ascertain family member participation to track 
segregation of identified variants in family to determine their pathogenicity. Alternatively, 
functional assays could be used to determine pathogenicity, should they exist for the given gene. 
In some cases, family member segregation can additionally be used to identify new genes 
associated with IPF. The use of whole-genome sequencing allows for the investigation of intronic 
variants, when no rare exonic variant is found. Future studies could determine if intronic variants 
affect the splicing patterns of the gene. 
3.5 CONCLUSION 
In this study we ascertained six pedigrees for individuals with IPF who have familial or 
sporadic disease. Four of these individuals had whole genome sequencing in which two individuals 
had rare variants in telomere pathway genes, RTEL1 and TERT. Two familial patients had no 
exonic variants identified, although this does not rule out the possibility of a gene not yet associated 
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with IPF or environmental exposures leading to IPF. Additionally, the two patients who do not yet 
have results from sequencing have pedigrees consistent with familial IPF and further concerns of 
telomere-mediated disease due to co-morbidities identified through the pedigree analysis. 
This study utilized whole-genome sequencing and was successful in identifying rare, 
exonic variants in two of the four patients. The data analysis focused on exonic variants and splice 
variants, although intronic variants can also contribute to disease. Further analysis of intronic 
variants are warranted and have been found, particularly when no exonic variants are disease-
causing.103 While not undertaken in this study, whole-genome sequencing can be used to measure 
telomere length, which would be important information to gather for these patients, due to the 
mechanism of telomere shortening in both familial and sporadic IPF.104  
Currently, clinical genetic testing is not the standard of care for IPF, however therapies are 
being developed based on the genetic status of a patient. These therapies can help personalize care 
and treatment, as well as limit risks and morbidity associated with lung transplant, which is the 
only life extending treatment. Further, these results may suggest genetic testing could yield 
relevant information in all patients with IPF, not just those with familial disease. This study, and 
others, have shown that more than 10% of individuals with sporadic IPF may have pathogenic 
variants in genes implicated in IPF. In some cases, it is possible reportedly sporadic IPF patients 
have other family members with this disease or associated malignancies but are unaware of these 
associations. It is important for physicians to ask appropriate family history questions to elucidate 
possible familial disease. 
Anecdotally, patients often show a strong interest in understanding this disease and its 
impact on their family as well as a desire to participate in research. As genetic information evolves 
and shifts into clinical practice, it will be imperative that patients are educated about the differences 
 40 
between clinical and research testing. This education is important for both patients and providers, 
in terms of genetic education and the role genetics plays in this disease. Finally, this study supports 
the importance of ascertaining pedigrees and family history information in patients with IPF, as it 
can provide valuable information as to the manifestations of the disease in families. 
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4.0  RESEARCH SIGNIFICANCE TO GENETIC COUNSELING AND PUBLIC 
HEALTH  
Although this thesis project studied a small subset of patients with pulmonary fibrosis, the 
results provide further evidence of the role genetics plays in pulmonary fibrosis, in both familial 
and sporadic cases. The American Thoracic Society (ATS) has set forth guidelines for the care and 
management of patients, though these guidelines do not include recommendations for genetic 
testing in this disease.20 However, research has demonstrated a relationship between telomere 
length and lung transplant outcome, suggesting genetic testing and genetic counseling has growing 
relevancy in this setting.13-15  
This research has public health implications. In public health, there are three core functions: 
assessment, policy development, and assurance.105 Policy development is particularly relevant to 
this study. Currently, there is no policy to guide genetic testing in these families, despite the 
preponderance of evidence regarding the implications of genetic information. Speculatively, 
policies may not exist because genetic testing has not been viewed as medically actionable. This 
is ethically problematic due to the relationship between shortened telomeres and outcomes post-
transplant. Recent studies have suggested considerations for genetic testing, though these are not 
official statements of ATS.106,107 In addition to these studies, recent research has suggested it may 
be time to consider clinical genetic testing for numerous reasons. One of these reasons is because 
patients want to know if their family members are at risk. Another reason is because of the 
possibility of modifying transplant protocols to improve the outcome for those undergoing a lung 
transplant. These alternative approaches aim to reduce morbidity and mortality and have been 
implicated in those with pathogenic variants in telomere genes or the presence of shortened 
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telomeres. As more research studies elucidate the genetic underpinnings of this disease, it will be 
imperative that policies are developed to ensure patients are provided the best possible care, which 
may include clinical genetic testing. 
 At the Simmons Center for Interstitial Lung Disease, many patients are quite invested in 
contributing to research studies that aim to enhance understanding of the disease and the 
development of therapeutic and treatment approaches. A difficulty with this study was helping 
participants distinguish between clinical and research testing, ensuring they understood that 
receiving results was not part of the study. This is a known difficulty in genetic studies and clinical 
trials, especially in regards to obtaining informed consent.108,109 In fact, physicians, nurses, and 
research coordinators have commented that patients frequently ask, “Is this [pulmonary fibrosis] 
something that my children will get?” Interacting with these patients and ascertaining their family 
histories, as well as consenting them for the study, has provided valuable insight into the 
importance of genetic counseling, especially if a patient was to undergo clinical testing. In addition 
to genetic counselors ensuring the distinction between clinical and research testing is explained, 
discussing the implications of this testing is essential, for both the patient and their family 
members. For the patient, it will be important to discuss what this testing is, how testing may 
impact their care, how IPF is inherited, and the possible impact of testing on insurance (via the 
genetic information non-discrimination act). For family members, this is an adult-onset condition, 
with variable penetrance and anticipation, making it difficult to determine their immediate risk. In 
addition, due to the lack of guidelines for genetic testing, there are no clear recommendation for 
the clinical management of unaffected carriers of pathogenic variants. Concerns related to 
insurance discrimination should be addressed when individuals consider predictive genetic testing. 
Overall, should genetic testing begin to be offered to patients, it will be important that genetic 
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counselors are available to discuss the many implications this testing may have, as well as the 
psychosocial concerns that may arise in order to best meet the needs of patients and their family 
members. 
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For further information, please contact the author. 
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